Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A case-controlled comparison of postoperative analgesic dosing between girls with Rett syndrome and girls with and without developmental disability undergoing spinal fusion surgery.

Barney CC, Merbler AM, Quest K, Byiers BJ, Wilcox GL, Schwantes S, Roiko SA, Feyma T, Beisang A, Symons FJ.

Paediatr Anaesth. 2017 Mar;27(3):290-299. doi: 10.1111/pan.13066. Epub 2017 Feb 8.

2.

Predictors of the nicotine reinforcement threshold, compensation, and elasticity of demand in a rodent model of nicotine reduction policy.

Grebenstein PE, Burroughs D, Roiko SA, Pentel PR, LeSage MG.

Drug Alcohol Depend. 2015 Jun 1;151:181-93. doi: 10.1016/j.drugalcdep.2015.03.030. Epub 2015 Apr 7.

3.

Brain extracellular γ-hydroxybutyrate concentrations are decreased by L-lactate in rats: role in the treatment of overdoses.

Roiko SA, Vijay N, Felmlee MA, Morris ME.

Pharm Res. 2013 May;30(5):1338-48. doi: 10.1007/s11095-013-0973-z. Epub 2013 Jan 15.

4.

Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats.

Roiko SA, Felmlee MA, Morris ME.

Drug Metab Dispos. 2012 Jan;40(1):212-8. doi: 10.1124/dmd.111.041749. Epub 2011 Oct 21.

5.

Mechanistic toxicokinetic model for gamma-hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy.

Felmlee MA, Wang Q, Cui D, Roiko SA, Morris ME.

AAPS J. 2010 Sep;12(3):407-16. doi: 10.1208/s12248-010-9197-x. Epub 2010 May 12.

6.

Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Felmlee MA, Roiko SA, Morse BL, Morris ME.

J Pharmacol Exp Ther. 2010 Jun;333(3):764-71. doi: 10.1124/jpet.109.165381. Epub 2010 Mar 9.

7.

Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing.

Riedl MS, Braun PD, Kitto KF, Roiko SA, Anderson LB, Honda CN, Fairbanks CA, Vulchanova L.

J Neurosci. 2009 Oct 21;29(42):13377-88. doi: 10.1523/JNEUROSCI.1127-09.2009.

8.

Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats.

Roiko SA, Harris AC, LeSage MG, Keyler DE, Pentel PR.

Pharmacol Biochem Behav. 2009 Aug;93(2):105-11. doi: 10.1016/j.pbb.2009.04.011. Epub 2009 Apr 23.

9.

Enhanced immunogenicity of a bivalent nicotine vaccine.

Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR.

Int Immunopharmacol. 2008 Nov;8(11):1589-94. doi: 10.1016/j.intimp.2008.07.001. Epub 2008 Jul 24.

10.

Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats.

Roiko SA, Harris AC, Keyler DE, Lesage MG, Zhang Y, Pentel PR.

J Pharmacol Exp Ther. 2008 Jun;325(3):985-93. doi: 10.1124/jpet.107.135111. Epub 2008 Feb 27.

PMID:
18305013
11.

Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.

Pentel PR, Dufek MB, Roiko SA, Lesage MG, Keyler DE.

J Pharmacol Exp Ther. 2006 May;317(2):660-6. Epub 2006 Jan 11.

PMID:
16407464
12.

Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships.

Keyler DE, Roiko SA, Benlhabib E, LeSage MG, St Peter JV, Stewart S, Fuller S, Le CT, Pentel PR.

Drug Metab Dispos. 2005 Jul;33(7):1056-61. Epub 2005 Apr 20.

PMID:
15843487

Supplemental Content

Loading ...
Support Center